Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn about a recent article by Lana A. Castellucci published in NEJM, adding:
“Two of the most commonly used anticoagulants in the world… but are they really equivalent?
For years, clinicians have treated apixaban and rivaroxaban as largely interchangeable for venous thromboembolism.
A new randomized trial published in NEJM challenges that assumption.
In the COBRRA trial, more than 2700 patients with acute VTE were randomized to apixaban or rivaroxaban. Striking results!
Clinically relevant bleeding
- Apixaban: 3.3%
- Rivaroxaban: 7.1%
That is about a 54% relative reduction in bleeding risk.
Importantly, this difference appeared within the first 3 months, the highest-risk phase of anticoagulation therapy.
Why this matters clinically?
- Anticoagulation decisions are rarely about efficacy alone.
- They are about balancing thrombosis prevention with bleeding risk.
- If two agents prevent clots similarly but one carries substantially less bleeding, that changes real-world prescribing decisions.
For clinicians managing:
- Pulmonary embolism
- Proximal DVT
- Early anticoagulation after diagnosis
These data may influence which DOAC becomes the default choice.
Bigger picture:
We often assume drugs within the same class behave the same.
But trial-level comparisons show us that pharmacology still matters.
Small differences in mechanism, dosing schedules, and pharmacokinetics can translate into meaningful differences for patients.
Curious how others are thinking about this.
Would this change your first-line DOAC choice in acute VTE?”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on NEJM
More posts featuring Akinchan Bhardwaj on Hemostasis Today.
-
Sep 10, 2026, 05:12Douglas S. Campbell: Great to See a Strong Japanese Presence in 2026 Lasker Awards
-
Sep 10, 2026, 05:11Jan Hartmann: New Transformative Treatment for Hemophilia A
-
Sep 10, 2026, 05:09Shelby Bradford: Award-Winning Science Incoming
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH